About The Author

Editorial & Columns

Insider or an Outsider as a CEO: Insights on Pharmaceutical Industry in India

March 20, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

On the Right Side of Regulations: The USFDA and Indian Pharmaceutical Companies

March 12, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

CSR by Pharmaceutical Companies and Engagement with SHGs, NGOs & Foundations

March 6, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Patent Cliff: Opportunity for Indian Pharmaceutical Companies

February 27, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Trump, Tariffs and Trade of Pharmaceuticals from India

February 17, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Make in India: PLI for Pharmaceutical Industry

February 11, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Union Budget 2025: Impact on Pharmaceutical Sector

February 7, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Trump, PEPFAR and Indian Pharmaceutical Industry

January 30, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Union Budget 2025: Expectations of Pharmaceutical Industry

January 24, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Product Portfolio of Top Indian Pharmaceutical Companies

January 15, 2025 | Dr. Anil Kumar Angrish | No Comments |

More